Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s
New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of
New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to
Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell
Company expands precision medicine solutions for drug development and clinical utility programs. LAUSANNE, SWITZERLAND - August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA,
Schweizer Firma erhält Felix Burda Award für Bluttest, der Darmkrebs erkennt Ein Biotech-Unternehmen hat einen Bluttest entwickelt, der Darmkrebs und dessen Vorstufen mit hoher Wahrscheinlichkeit erkennt. Die Basis dafür bilden Biomarker im Blut. Für diesen Fortschritt in der Darmkrebs-Vorsorge erhalten sie den Felix Burda Award 2021. Im zweiten Teil der virtuellen Preisverleihung geht der